Solitary solutions to an androgen-deprivation prostate cancer treatment model

被引:3
|
作者
Telksnys, T. [1 ]
Timofejeva, I. [1 ]
Navickas, Z. [1 ]
Marcinkevicius, R. [2 ]
Mickevicius, R. [3 ]
Ragulskis, M. [1 ]
机构
[1] Kaunas Univ Technol, Ctr Nonlinear Syst, Studentu 50-147, LT-51368 Kaunas, Lithuania
[2] Kaunas Univ Technol, Dept Software Engn, Studentu 50-415, LT-51368 Kaunas, Lithuania
[3] Lithuanian Univ Hlth Sci, Urol Clin, Eiveniu 2, LT-50009 Kaunas, Lithuania
关键词
androgen deprivation therapy; prostate cancer model; solitary solution; IDENTIFICATION; SYSTEMS;
D O I
10.1002/mma.6168
中图分类号
O29 [应用数学];
学科分类号
070104 ;
摘要
A model of androgen deprivation treatment for prostate cancer is considered in this paper. Bright/dark solitary solutions to the model are constructed using inverse balancing and generalized differential operator techniques. It is shown that solitary solutions correspond to biomedically relevant sets of model parameters. Dynamical properties of solitary solutions are analyzed in the phase plane. It is demonstrated that such solutions closely reflect the real-world phenomena observed during androgen deprivation treatment. Computational experiments are used to illustrate these effects.
引用
收藏
页码:3995 / 4006
页数:12
相关论文
共 50 条
  • [21] Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer
    Gupta, Dipti
    Chuy, Katherine Lee
    Yang, Ji Can
    Bates, Megan
    Lombardo, Marissa
    Steingart, Richard M.
    JOURNAL OF ONCOLOGY PRACTICE, 2018, 14 (10) : 580 - +
  • [22] Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer REPLY
    Shahinian, Vahakn B.
    Kuo, Yong-Fang
    Gilbert, Scott M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (06): : 580 - 580
  • [23] Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer
    Harrington, Joanne M.
    Schwenke, Dawn C.
    Epstein, Dana R.
    Bailey, Donald E., Jr.
    ONCOLOGY NURSING FORUM, 2014, 41 (01) : 21 - 29
  • [24] Androgen-Deprivation Therapy and Cardiovascular Disease Risk - The Role of Exercise in prostate Cancer Treatment
    Wall, Bradley
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [25] Age and androgen-deprivation therapy on exercise outcomes in men with prostate cancer
    Alberga, Angela S.
    Segal, Roanne J.
    Reid, Robert D.
    Scott, Chris G.
    Sigal, Ronald J.
    Khandwala, Farah
    Jaffey, James
    Wells, George A.
    Kenny, Glen P.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (05) : 971 - 981
  • [26] Re: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    不详
    JOURNAL OF UROLOGY, 2021, 205 (01): : 303 - 304
  • [27] Harms of Intermittent vs Continuous Androgen-Deprivation Therapy for Prostate Cancer
    Niraula, Saroj
    Tannock, Ian F.
    JAMA ONCOLOGY, 2016, 2 (04) : 461 - 462
  • [28] Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer
    Chow, Alexander K.
    Vourganti, Srinivas
    Konety, Badrinath R.
    EUROPEAN UROLOGY, 2021, 80 (03) : 386 - 386
  • [29] Immediate versus deferred androgen-deprivation therapy for localized prostate cancer
    Nature Clinical Practice Urology, 2006, 3 (7): : 348 - 349
  • [30] Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer
    Cattrini, Carlo
    Zanardi, Elisa
    Boccardo, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) : 2350 - +